Short term curative effect of NB09 protocol on high-risk and ultra-high-risk neuroblastoma
10.11958/j.issn.0253-9896.2015.02.020
- VernacularTitle:NB09方案治疗高危和极高危神经母细胞瘤近期疗效观察
- Author:
Chanjuan WEI
;
Qiang ZHAO
;
Jie YAN
;
Jingfu WANG
;
Zhanglin LI
;
Yanna CAO
;
Jie LI
- Publication Type:Journal Article
- Keywords:
neuroblastoma;
antineoplastic combined chemotherapy protocols;
treatment outcome;
child;
clinical charac-teristics
- From:
Tianjin Medical Journal
2015;(2):189-192
- CountryChina
- Language:Chinese
-
Abstract:
Objective To evaluate the clinical outcome of NB09 (China Pediatric Neuroblastoma cooperative group 09) protocol on children with high-risk and ultra-high risk neuroblastoma. Methods The clinical and follow-up data of pa?tients who suffered from high-risk (n=7) and ultra-high risk (n=31) neuroblastomas and admitted in Tumor hospital of Tian?jin Medical University between January 2009 to January 2013 were retrospectively reviewed (27 boys and 11 girls). The age at diagnosis was 19-160 months (median age was 36.5 months). In the high risk group, patients were evaluated and operated after 4 to 6 circles of neoadjuvant chemotherapy. In ultra-high risk group, patient received chemotherapy before and after op?eration, then autologous stem cell transplantation and tumor bed radiotherapy. After chemotherapy, retinoic acid treatment was given to patients in ultra high risk group as in high risk group. Results At the end of treatment, 25 patients achieved complete remission; 5 patients achieved partial remission; 3 patients were in stable disease;5 patients were deteriorating in their conditions which lead to 2 deaths. In total, the response rate reaches upto 86.8%. By the end of follow up, 15 patients had a disease-free-survival, 9 patients survived with tumor, 7 died from recurrence and 7 died from deteriorating conditions. Survival time ranged from 6 to 52 months (median survival 25.5 months). The 1-, 2- and 3-year overall survival were 91.7%, 64.5%and 57.3%respectively. Kaplan-Meier curve and Log-rank test showed no statistical significance between high risk and ultra-high risk neuroblastomas. Conclusion The outcome of NB09 protocol for high risk and ultra-high risk neuroblastoma was preliminary affirmed. It is worthy of further clinical verification.
